FDA Novel Drugs
Generic Name: Linerixibat
- Brand Name: Lynavoy
- Drug Class: Ileal bile acid transporter (IBAT) inhibitor
- Sponsor by: GlaxoSmithKline
- Approval Date: 19/03/2026
Lynavoy (linerixibat) is an oral ileal bile acid transporter (IBAT) inhibitor developed by GSK (GlaxoSmithKline) for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.
Author: Darshan Singh
Generic Name: navepegritide
- Brand Name: Yuviwel
- Drug Class: CNP analog prodrug
- Sponsor by: Ascendis Pharma Growth Disorders A/S
- Approval Date: 27/02/2026
Overview Yuviwel (navepegritide) is a once‑weekly, subcutaneous C‑type natriuretic peptide (CNP) analog approved by the U.S. Food and Drug Administration in February 2026 to increase linear growth in pediatric patients
Author: Darshan Singh
Generic Name: pegzilarginase‑nbln
- Brand Name: Loargys
- Drug Class: Enzyme replacement therapy
- Sponsor by: Immedica Pharma AB / Immedica Pharma US Inc.
- Approval Date: 23/02/2026
Loargys (pegzilarginase‑nbln) is a pegylated, cobalt‑substituted recombinant human arginase‑1 enzyme granted accelerated FDA approval on 23 February 2026 for treatment of hyperargininemia in adults and children 2 years and older
Author: Darshan Singh
Generic Name: milsaperidone
- Brand Name: BYSANTI
- Drug Class: Small molecule
- Sponsor by: Vanda Pharmaceuticals
- Approval Date: 20/02/2026
The formal approval of Bysanti (milsaperidone) by the United States Food and Drug Administration (FDA) on February 20, 2026, signifies a sophisticated regulatory and pharmacological evolution within the atypical antipsychotic
Author: Darshan Singh
Generic Name: Difamilast
- Brand Name: Adquey
- Drug Class: Small molecule
- Sponsor by: Otsuka Pharmaceutical
- Approval Date: 12/02/2026
On February 12, 2026, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for ADQUEY™ (difamilast 1%) ointment for the topical treatment of mild-to-moderate atopic dermatitis
Author: Darshan Singh
Generic Name: copper histidinate
- Brand Name: ZYCUBO
- Drug Class: Gene
- Sponsor by: Sentynl Therapeutics
- Approval Date: 12/01/2026
On January 12, 2026, the U.S. Food and Drug Administration (FDA) officially approved ZYCUBO® (copper histidinate) for injection, marking a historic achievement as the first and only approved treatment for
Author: Darshan Singh
Generic Name: tradipitant
- Brand Name: NEREUS™.
- Drug Class: Others
- Sponsor by: Vanda Pharmaceuticals Inc.
- Approval Date: 30/12/2025
On December 30, 2025, the U.S. Food and Drug Administration (FDA) approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion in adults[1].
Author: Darshan Singh
Generic Name: narsoplimab-wuug
- Brand Name: YARTEMLEA
- Drug Class: MASP-2
- Sponsor by: Omeros Corporation
- Approval Date: 23/12/2025
On December 23, 2025, the U.S. Food and Drug Administration (FDA) approved Yartemlea (narsoplimab-wuug), a novel MASP-2 inhibitor developed by Omeros Corporation. This marks a significant regulatory milestone as Yartemlea